Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Issue 8 (19th June 2018)

• Record Type: Journal Article
• Authors: Chen, Grace; Nomikos, George G.; Affinito, John; Jacobson, William; Zhao, Zhen; Wang, Shining; Xie, Jinhui
• Is Part Of: Clinical pharmacology in drug development. Volume 7:Issue 8(2018)
• Page Start: 880
• Page End: 888
• Publication Date: 2018-06-19
• Subjects: vortioxetine -- pharmacokinetics -- age -- sex -- race -- hepatic impairment -- renal impairment -- adverse events; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.577
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: Vortioxetine is an antidepressant agent with multimodal activity that is approved for the treatment of major depressive disorder at doses of 5 to 20 mg once daily. Vortioxetine is a medium‐clearance drug that undergoes extensive metabolism via several cytochrome P450 isozymes. A series of single‐ and multiple‐dose pharmacokinetic studies were performed to evaluate the impact of intrinsic (ie, subject‐related) factors, such as age, sex, race, and renal and hepatic function, on the pharmacokinetics of vortioxetine. The point estimates on the ratios and their 90% confidence intervals (CIs) for the central values of AUC (area under the concentration‐time curve) and Cmax (maximum plasma concentration) were obtained by taking the antilog of the differences and 90%CIs in the log‐transformed least‐squares means. The results demonstrate that there were no clinically meaningful differences (defined as exposure difference between 50% and 2‐fold change) in the exposure to vortioxetine (as assessed by AUC and Cmax ) between elderly and younger subjects, men and women, and blacks and whites and among subjects with varying degrees of renal or hepatic impairment. These results suggest that no dosing adjustments of vortioxetine are required for the intrinsic factors investigated in these studies.